SCHEMBL6693555

SCHEMBL6693555

COC(=O)c1cccc2c1c1c(O)cccc1n2Cc1cc(C)cc(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 7/20 0.42
THRB P10828 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LMNA P02545 2/20 0.42
TSHR P16473 2/20 0.42
PLA2G2A P14555 2/20 0.41
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
ALDH1A1 P00352 3/20 0.39
PKM P14618 1/20 0.39
KDM4E B2RXH2 2/20 0.39
POLB P06746 1/20 0.39
TP53 P04637 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6690384 0.92 MAPT (0.52) GAAL3MBTL1NPSR1MAPTTHRB
SCHEMBL5210919 0.86 PLA2G2A (0.52) GAAMAPTTHRBLMNATSHR
SCHEMBL6691521 0.86 MAPT (0.49) GAAL3MBTL1NPSR1MAPTTHRB
SCHEMBL6694031 0.85 PLA2G2A (0.48) MAPTTSHRPLA2G2AF2F10
SCHEMBL6689196 0.85 GAA (0.47) GAAL3MBTL1NPSR1MAPTTHRB
SCHEMBL6899653 0.84 F10 (0.42) MAPTTHRBSMN1; SMN2LMNATSHR
SCHEMBL6689284 0.84 L3MBTL1 (0.49) GAAL3MBTL1MAPTSMN1; SMN2LMNA
SCHEMBL6691704 0.84 F10 (0.42) GAAL3MBTL1MAPTTHRBSMN1; SMN2
SCHEMBL6694412 0.84 PLA2G2A (0.56) MAPTTHRBSMN1; SMN2PLA2G2AF10
SCHEMBL6896918 0.83 SLC6A2 (0.43) LMNATSHRPLA2G2AF10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed